TriangleDurvalumab + Tremelimumab (NCT05932199)
Durvalumab + Tremelimumab trial for Resectable Pleural Mesothelioma (NCT05932199). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with pleural mesothelioma that can likely be removed with surgery.
The idea: give immunotherapy before surgery. One group gets durvalumab and tremelimumab, two antibodies that release brakes on the immune system. Another group gets the same two drugs plus platinum and pemetrexed chemotherapy. Each group gets three cycles by vein, then surgery.
The study looks at whether patients stay free of cancer longer, and at safety.
This phase 1 and 2 study plans 52 patients. At Baylor College of Medicine in Houston, Robert Ripley leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.